ANXA3 and prostate carcinoma: Regarding its clinical relevance, high ANXA3 expression has been correlated with a poor prognosis in gastric, hepatocellular and breast carcinomas (Liu C. et al., 2021), and it has also been proposed as a diagnostic marker in prostate cancer (Schostak et al., 2009).